Group 1 - The core viewpoint of the article highlights the significant rise in the stock price of Heptagon Pharmaceuticals-B (2142.HK), which increased by 4.79% to reach a historical high of 17.95 HKD, marking an 865% increase year-to-date and a market capitalization exceeding 15.6 billion HKD [1] - The company announced the successful completion of a share placement on September 5, 2025, with 45.022 million shares sold at a price of 11.50 HKD per share, resulting in a net amount of approximately 512 million HKD after commissions and related expenses [1] - The board believes that the share placement will broaden the shareholder base and enhance the capital foundation, providing greater financial flexibility and necessary resources for strategic and business growth [1] Group 2 - The net proceeds from the share placement will be allocated to several areas, including 256 million HKD (50%) for the continued development of innovative drugs, 205 million HKD (40%) for clinical trials of existing pipeline drugs, and 51.2 million HKD (10%) for working capital and general operational purposes [1]
港股异动丨和铂医药涨超4% 股价续创历史新高 年内飙升超8倍！